Relevance to NICE guidance programmes
The use of the OraQuick HCV is not currently planned into any NICE guidance programme.
NICE has issued the following guidance relevant to this briefing:
-
Hepatitis B and C: ways to promote and offer testing to people at increased risk of infection (2012) NICE public health guidance 43
-
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (2010) NICE technology appraisal guidance 200
-
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (2004) NICE technology appraisal guidance 75
-
Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (2006) NICE technology appraisal guidance 106
-
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (2013) NICE technology appraisal guidance 300
-
Telaprevir for the treatment of genotype 1 chronic hepatitis C (2012) NICE technology appraisal guidance 252
-
Boceprevir for the treatment of genotype 1 chronic hepatitis C (2012) NICE technology appraisal guidance 253